Opus Genetics, Inc. SEC filings IRD
Opus Genetics, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jun 17, 2005. Its latest annual report, Form ARS, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 21, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 14, 2026 | — |
| CORRESP | Letter to the SEC | Aug 13, 2026 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2026 | — |
| EFFECT | Filing | Jun 15, 2026 | — |
| CORRESP | Letter to the SEC | Jun 11, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 10, 2026 | — |
| EFFECT | Filing | Apr 22, 2026 | — |
| CORRESP | Letter to the SEC | Apr 21, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 17, 2026 | — |
| PX14A6G | Filing | Apr 11, 2025 | — |
| EFFECT | Filing | Apr 10, 2025 | — |
| DFAN14A | Filing | Apr 9, 2025 | — |
| CORRESP | Letter to the SEC | Apr 9, 2025 | — |
| CORRESP | Letter to the SEC | Apr 8, 2025 | — |
| CORRESP | Letter to the SEC | Apr 7, 2025 | — |
| PRRN14A | Filing | Apr 4, 2025 | — |
| DEFC14A | Preliminary proxy statement | Apr 2, 2025 | — |
| DFAN14A | Filing | Apr 2, 2025 | — |
| PRER14A | Preliminary proxy statement | Mar 31, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 28, 2025 | — |
| DFAN14A | Filing | Mar 28, 2025 | — |
| DFAN14A | Filing | Mar 21, 2025 | — |
| PRER14A | Preliminary proxy statement | Mar 21, 2025 | — |
| PREC14A | Filing | Mar 21, 2025 | — |
| PREC14A | Preliminary proxy statement | Mar 20, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 26, 2025 | — |
| DFAN14A | Filing | Feb 7, 2025 | — |
| D | Filing | Nov 7, 2024 | — |
| DEFR14A | Filing | May 30, 2024 | — |
| EFFECT | Filing | Jan 23, 2024 | — |
| CORRESP | Letter to the SEC | Jan 22, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2023 | — |
| CORRESP | Letter to the SEC | Jul 7, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 28, 2023 | — |
| EFFECT | Filing | Feb 12, 2021 | — |
| CORRESP | Letter to the SEC | Feb 11, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 10, 2021 | — |
| D | Filing | Nov 20, 2020 | — |
| 425 | 8-k | Nov 3, 2020 | — |
| 425 | Filing | Oct 20, 2020 | — |
| 425 | Filing | Oct 16, 2020 | — |
| 425 | 8-k | Oct 9, 2020 | — |
| EFFECT | Filing | Oct 2, 2020 | — |
| SEC STAFF LETTER | Filing | Oct 2, 2020 | — |
| CORRESP | Letter to the SEC | Sep 30, 2020 | — |
| CORRESP | Letter to the SEC | Sep 30, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 24, 2020 | — |
| CORRESP | Letter to the SEC | Sep 15, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 10, 2020 | — |
| SEC STAFF LETTER | Filing | Sep 1, 2020 | — |
| CORRESP | Letter to the SEC | Aug 27, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 3, 2020 | — |
| 425 | Form 8-k | Jul 1, 2020 | — |
| 425 | 8-k | Jun 19, 2020 | — |
| 425 | Filing | Jun 18, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 7, 2019 | — |
| SEC STAFF LETTER | Filing | Oct 7, 2019 | — |
| SEC STAFF LETTER | Filing | Aug 15, 2019 | — |
| CORRESP | Letter to the SEC | Jul 26, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2019 | — |
| CERT | Filing | Jun 10, 2019 | — |
| 8-A12B | 8-a 12b | Jun 7, 2019 | — |
| 25 | Filing | Jun 7, 2019 | — |
| CT ORDER | Filing | Dec 17, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 19, 2018 | — |
| CORRESP | Letter to the SEC | Jul 18, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 13, 2018 | — |
| EFFECT | Filing | Jul 11, 2017 | — |
| CORRESP | Letter to the SEC | Jul 7, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2016 | — |
| CORRESP | Letter to the SEC | Oct 14, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2016 | — |
| EFFECT | Filing | Jun 26, 2014 | — |
| CORRESP | Letter to the SEC | Jun 25, 2014 | — |
| UPLOAD | Letter from the SEC | Jun 5, 2014 | — |
| EFFECT | Filing | Jul 5, 2011 | — |
| UPLOAD | Letter from the SEC | Mar 23, 2011 | — |
| CORRESP | Letter to the SEC | Mar 22, 2011 | — |
| CORRESP | Letter to the SEC | Mar 18, 2011 | — |
| CORRESP | Letter to the SEC | Jan 19, 2011 | — |
| CORRESP | Letter to the SEC | Jan 6, 2011 | — |
| UPLOAD | Letter from the SEC | Dec 22, 2010 | — |
| CORRESP | Letter to the SEC | Dec 3, 2010 | — |
| CORRESP | Letter to the SEC | Nov 24, 2010 | — |
| CORRESP | Letter to the SEC | Oct 15, 2010 | — |
| CORRESP | Letter to the SEC | Oct 1, 2010 | — |
| UPLOAD | Letter from the SEC | Sep 17, 2010 | — |
| NT 10-Q | Filing | May 18, 2010 | Mar 31, 2010 |
| CT ORDER | Filing | Nov 20, 2009 | — |
| CT ORDER | Filing | Nov 20, 2009 | — |
| NT 10-Q | Filing | Nov 9, 2009 | Sep 30, 2009 |
| UPLOAD | Letter from the SEC | Mar 2, 2009 | — |
| CORRESP | Letter to the SEC | Mar 2, 2009 | — |
| UPLOAD | Letter from the SEC | Feb 25, 2009 | — |
| EFFECT | Filing | Aug 8, 2008 | — |
| CERTAMX | Auto-generated paper document | May 27, 2008 | — |
| 8-A12B | Rexahn pharmaceuticals 8-a12b 5-22-2008 | May 23, 2008 | — |
| 10KSB | Rexahn pharmaceutical inc 10ksb 12-31-2007 | Mar 31, 2008 | Dec 31, 2007 |
| REGDEX | Auto-generated paper document | Jan 8, 2008 | — |
| PRER14C | Rexahn pharmaceuitcals prer 14c 12-4-2007 | Dec 4, 2007 | — |
| 10QSB | Rexahn pharmaceuticals inc 10-qsb 9-30-2007 | Nov 14, 2007 | Sep 30, 2007 |
| 10QSB | Rexahn pharmaceuticals 10-qsb 6-30-2007 | Aug 14, 2007 | Jun 30, 2007 |
| 10QSB | Rexahn 10qsb 3-31-2007 | May 15, 2007 | Mar 31, 2007 |
| 10KSB | Rexahn 10-ksb 12-31-2006 | Apr 2, 2007 | Dec 31, 2006 |
| 10QSB | Rexahn pharmaceuticals 10qsb 9-30-2006 | Nov 14, 2006 | Sep 30, 2006 |
| 10QSB | Rexahn pharmaceuticals 10-qsb 6-30-2006 | Aug 14, 2006 | Jun 30, 2006 |
| 10QSB | Rexahn pharmaceuticals inc. 10-qsb 3-31-2006 | May 15, 2006 | Mar 31, 2006 |
| 10KSB | Rexahn pharmaceuticals 10ksb 12-31-2005 | Mar 31, 2006 | Dec 31, 2005 |
| 10QSB | Rexahn parmaceuticals 10-qsb 9-30-2005 | Nov 14, 2005 | Sep 30, 2005 |
| 10QSB | Quarterly report | Aug 23, 2005 | Jun 30, 2005 |
| NT 10-Q | Notification of late filing | Aug 16, 2005 | Jun 30, 2005 |
Showing 113 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IRD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1228627
- Former names
- Ocuphire Pharma, Inc. (until Oct 22, 2024); REXAHN PHARMACEUTICALS, INC. (until Nov 9, 2020); CORPORATE ROAD SHOW DOT COM INC (until Apr 29, 2005); FERRARO FRANK (until Apr 29, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.